Likvor receives an order for CELDA from the University Hospital in Linköping
Likvor receives an order for CELDA™ from the University Hospital
in Linköping
LinkMed's portfolio company Likvor has received an order
for Likvor CELDA™ from the University Hospital in
Linköping. With Likvor
CELDA™ the clinic will be able to dynamic
measure the most important parameters concerning the patients'
cerebrospinal fluid including pressure and flow in a controlled and
safe process. Likvor CELDA™ was developed to
facilitate greater understanding and enhance diagnosis of normal
pressure hydrocephalus (NPH), a condition that is often mistaken
for dementia. This is the fourth order for the instrument since it
got CE marked.
Likvor CELDA™ is the first commercially approved instrument for
assessing the flow of CSF fluid that surrounds the brain and spinal
cord. It increases the possibility for patients who suffer from NPH
to receive a correct diagnosis and therefore the appropriate
treatment in the form of a shunt implant that diverts and regulates
CSF pressure and flow. An accurate diagnosis means large gains for
the patient and family, but also for society as a whole.
Likvor CELDA™ is used with a special developed catheter, CELDA
TOOLS™ that is a disposable for one time use only.
Hidden disease of old age
Normal Pressure Hydrocephalus (NPH) is a relatively unknown
disease that is often mistakenly diagnosed as dementia, Alzheimer's
or Parkinson's. The is because the symptoms, including disturbances
in gait, confusion and urinary incontinence, are similar to those
of dementia, plus that NPH is a condition that mainly occurs in
people over the age of 55. Studies have shown that up to 10 percent
of dementia patients may actually be suffering from NPH. In Sweden
it is estimated that over 7,000 Swedes suffer from the disease -
most of them unnecessarily. In the U.S., the corresponding figure
is well over 375,000. NPH is a condition that is relatively easily
treated by the insertion of a shunt, which helps the patient to
regulate CSF flow and pressure.
Likvor's principal owners are Uminova Invest and LinkMed. For
more information about Likvor, please visit www.likvor.com.
For more information please contact:
Kjell Öberg, CEO Likvor: +46 70 640 14 92
Okee Williams, Portfolio Manager LinkMed: +46 70 600 5364
Agneta Edberg, Head of Sales and Marketing Likvor +46 70 555
7518
Press release: January 15, 2010